Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials. - Wikidata - awgldk - TriplyDB

Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials.

Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials.

http://www.wikidata.org/entity/Q36914483

about

Data resources for the identification and interpretation of actionable mutations by clinicians.Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development.Enhancing value of clinical pharmacodynamics in oncology drug development: An alliance between quantitative pharmacology and translational science.Determinants of the recommended phase 2 dose of molecular targeted agents.Mechanistic and pharmacologic insights on immune checkpoint inhibitors.The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017).Burdensome Research Procedures in Trials: Why Less Is More.Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection.Underreporting of Research Biopsies from Clinical Trials in Oncology.Implementation of a Multicenter Biobanking Collaboration for Next-Generation Sequencing-Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies.

P2860

Q36317783-1060E20E-B6E9-48BB-BC45-D34362BF34AB Q38818203-35158869-0733-4E7A-9AE1-8712DF8ADB9B Q38996431-51113EAE-0E75-43EE-ACE6-F2536F15E536 Q39128248-CA8A6E09-8287-4200-AE1F-849D522D0348 Q39190066-D5E33963-7B4D-4A2B-A44F-8F6CAFF146A4 Q47161072-3CE3DC62-4F47-4F24-A593-90D247536F07 Q47926951-AD7DFA98-6653-41CE-B6D0-D7D1003A04F9 Q50041876-4F58063C-069D-49BC-B0E4-763471C3CAD7 Q50517279-5398353C-64D3-499B-B73A-2319AE5AA175 Q51796512-0BE49D66-D1D9-4BDE-8730-C8DEFC0C2929

P2860

Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials.

http://www.wikidata.org/entity/Q36914483

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials.

@en

type

label

Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials.

@en

prefLabel

Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials.

@en

P1433

Q36914483-BAFCC241-DA68-4B4A-864D-4C45DEBE698F

P1476

Q36914483-C9CB22B8-7FB4-4AF0-A7DA-447D080B523F

P2093

Q36914483-AB627A32-58DF-4601-9929-4FA9A44A3DD2

P2860

Q36914483-09AD3527-CA2F-4920-B8E3-E57C8D6A2E91

Q36914483-3C600A79-CBBE-4AB9-B83F-0BB6B00E30A4

Q36914483-591CEE84-D6C3-4FA2-B3FF-BF7B48560686

Q36914483-6E3D7A63-FDFD-49B1-8FC0-3215BEC9DA39

Q36914483-8AAC41BF-A6C7-4E4D-8E7E-D57AAC294BAD

Q36914483-9691A2C8-13CD-4B3E-AF60-FF25BB666F6B

Q36914483-AA8E1E6F-EB90-44BC-84C6-1D65FC15C0D8

Q36914483-C6FD53C1-89C0-4671-8074-59C974DC8770

Q36914483-D18D647D-31BB-420A-8470-2FCA3AAB31C0

Q36914483-D3BACC60-07B8-479F-AC2B-DA58BD1FFB7A

P304

Q36914483-BBB47A75-3138-47B2-BBF9-9047E865BE60

P31

Q36914483-2AC67F21-D62C-4B79-88FE-14AC03283FF3

P356

Q36914483-EF269BEA-3999-4A9F-B8D7-6859C3DAFE37

P407

Q36914483-46690D92-A23D-44F5-AC0E-849272E46637

P433

Q36914483-CA6D8367-80CB-4933-8B3B-2219F938C9B5

P478

Q36914483-8229CB35-D409-4D81-A9A1-FC0AB691A23A

P50

Q36914483-24EF7419-49FB-4E0B-8B07-D565818BBDF3

Q36914483-C67E3B71-ECBE-4D3A-8516-5A524267C7D4

P577

Q36914483-3053F714-F39A-43E2-9786-92AEEEED4765

P698

Q36914483-5BAB57F2-5E17-4E56-A695-FFA250919E4E

P921

Q36914483-1927D6B0-DE6C-4384-951E-A91E61A1AC2E

P932

Q36914483-01267180-468B-43E5-AE7E-08D504EDBA1C

P356

JCO.2015.63.6126

P1433

Journal of Clinical Oncology

P1476

Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials

@en

P2093

Michael W Drazer

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I trials of antitumour agents: fundamental concepts

Pharmacodynamic biomarkers for molecular cancer therapeutics

How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development.

Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents.

Trends in the use and role of biomarkers in phase I oncology trials.

Reporting practices of pharmacodynamic studies involving invasive research procedures in cancer trials.

Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.

Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.

Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

P304

369-374

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2015.63.6126

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-12-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26668350

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

4872035

http://www.w3.org/2001/XMLSchema#string